Innovative science alone will not end TB, it is just the start. True impact needs trials, policies and real-world action. UNITE4TB interviewed stakeholders to understand challenges & opportunities in turning TB innovation into real impact. Read complete paper at: https://bit.ly/4pe6GtB

Want to stay up to date with the project updates ? Our upcoming newsletter is the easiest way! 📰 Every edition will bring you: ✅ Latest project updates ✅ Exclusive interviews with our researchers ✅ Insights into the latest advances in tackling AMR 👉 Sign up now: https://bit.ly/4qDXxMj

In the EU/EEA, drug-resistant infections costs nearly EUR 11.7B per year. This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost. 👉 Read the complete paper at: https://bit.ly/46VoQsf

One of the major reason for unsuccessful outcomes are the adverse events (AEs) from TB medications, which can disrupt treatment and reduce success rates. Dr. Simon Tiberi shared practical advice for healthcare teams to prevent treatment interruptions. Learn more: https://bit.ly/4qqxfgu

In our latest study, under UNITE4TB we explore how biomarkers are closing the gap, particularly in challenging cases such as low bacterial load, inability to produce sputum or smear-negative TB. 👉 Read full paper at: https://bit.ly/4ohCFZn

Webinar registration is now open! Join COMBINE, ERA4TB & GNANOW on October 21, Tuesday from 15:00–16:30 CEST for insights on Hollow Fiber Assays in antimicrobial drug development with three experts, Prof. Das, S. Ramon-Garcia & Prof. MacGowan. 👉 Register now: https://bit.ly/3VN3Sa5

Our latest research under @era4tb.bsky.social, highlights that small adjustments in the hollow fiber assays better reflects how TB drugs really perform. Learn more through a webinar on 21 October 2025. 👉 Research paper: https://bit.ly/4q7jIKE 👉 Webinar registration: https://bit.ly/3VN3Sa5

The COMBINE consortium met in Toulouse for its sixth annual meeting and focus is now on making our AMR Accelerator impact last. How do we plan to do that? By keeping datasets FAIR, preserving consortium expertise and embedding results in European & global research infrastructures.

In our latest study under RespiriNTM, zebra fish helped our researchers model nontuberculous mycobacterial infection. Why? Their immune system mirrors humans, letting us study infections effectively and ethically. 👉 Read more at: https://bit.ly/4pS8HwB 👉 Open manuscript: https://bit.ly/3KzNEi8

We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts. 👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁: Building effective hollow fibre systems Case studies Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models 👉 Register now: https://bit.ly/3VN3Sa5

Medicines need a reliable teammate to work effectively against resistant bacteria. And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria. 👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi

ERA4TB Webinar 📣 How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨ 🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST 🎙️ Speakers from NICE & WHO 👉 Register: tinyurl.com/ERA4TB @amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social

Our researchers found a missing link in applying ML to AMR: lack of clinical and preclinical data. We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG. Listen to webinar to learn more: bit.ly/472Q8y4

In our latest study, under UNITE4TB consortium, researchers describe how AI could become a powerful ally against TB at the same time highlight challenges that come with this new tech. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m

ERA4TB Webinar 📣 How can health systems respond to #AMR through innovation & evidence-based policy? 🌍 Join our ERA4TB webinar 🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST 🎙️ Speakers from @NICEComms & @WHO 👉 Register: tinyurl.com/ERA4TB @amr-accelerator.bsky.social @who.int @nicecomms.bsky.social

Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to). 🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for #tuberculosis.

Across the EU/EEA, resistant infections add over 9.5M extra hospital days annually. In a study conducted under PrIMAVeRa, our researchers used Bayesian analysis to show each resistant infection adds ~1–2 days, with variable extra costs. 👉 Read more: https://bit.ly/468S1co

Of all the buzzwords this year, none spread faster than "superbugs"! Used in the titles or main public messaging by over half a dozen of major news stories & campaigns (Mar–Sep 2025). Catchy, but does it oversimplify AMR or mislead the public? Share your thoughts on main drawback of this framing.

@era4tb.bsky.social researchers found compounds that block TB’s ESX-1 system (used to damage immune cells) while also improving effectiveness of ethionamide. A dual-action step against drug-resistant TB. 👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw

Why understanding the right dose matters in anti-TB treatment? We broke it down 👇 for you from the start to finish. 👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth 🔗 https://bit.ly/45QUyYB

“Supercontactors” are the hubs of hospital networks. Controlling their interactions, can help dramatically slow down the spread. Our latest PrIMAVeRa study showcases that targeting them reduced MRSA cases by about 20%. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo

In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress. 👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v

TB bacteria inhabits the air we breathe, exposing most people unknowingly. Yet only 5–10% develop active disease. Research under RespiriNTM and RespiriTB tested amiodarone, to boost immunity by enhancing autophagy against TB. 👉 Read: https://bit.ly/47QD53J

Regulators are not just “approvers,” in AMR R&D they guide the path. The WHO 2025 AMR plan stresses how early advice, adaptive pathways & collaboration can speed safe, effective solutions. Lets us know in comments 👇, do you know what support regulators give developers?

Is monitoring aggregate AMR data enough, or does it hide the gaps? Resistance varies across Europe, and overall prevalence masks the highest-burden regions. The PrIMAVeRa study maps pathogen-specific morbidity and mortality. 👉 Read more: https://bit.ly/3UCvWwk

In 2020, 1,800 immuno-oncology drugs were in development, and only 41 new antimicrobials made trials. Meanwhile, 10.8M people fell ill with TB in 2023. Why such a huge gap? We broke it down into clinical & commercial barriers in TB drug development. Learn more at: https://youtu.be/n6NxPFxHOys

𝗜𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗧𝗕 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲? Yes it can be, if patients can continue. 𝗧𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲? Complex dosing regimens reduce adherence. A UNITE4TB study, models 𝗼𝗻𝗰𝗲-𝗱𝗮𝗶𝗹𝘆 regimens for bedaquiline and delamanid. 👉Read here: https://bit.ly/45estKn

TB care starts in communities, where CSOs help guide and support care, adherence & recovery. True progress needs equal partnerships, yet the sustained funding lags. Join UNITE4TB & ERS panel on meaningful TB community engagement: bit.ly/412Cyrf

𝗛𝗼𝘄 𝘁𝗼 𝘁𝗿𝗮𝗰𝗲 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗮𝗱𝗶𝗼𝘁𝗿𝗮𝗰𝗲𝗿𝘀? With more safer and faster approach? Researchers under TRIC-TB consortium used ¹⁹F-NMR, ¹H-NMR & HR-MS to profile alpibectir. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁 https://bit.ly/4muyHLJ

Everyone in the antimicrobial resistance ecosystem stands to gain clearer direction, better tools and stronger collaboration with this WHO roadmap (2024–2030). AMR is not just scientific or clinical problem, but a systemic challenge needing multisectoral solutions. 🔗 https://bit.ly/4opZATc

TB survives by fueling its metabolism through a tricky enzyme, cytochrome bc1:aa3. So how do we starve it? Inhibiting isn’t enough, we need to know exactly how it’s blocked. Our new study under Respiri TB, reveals this in detail. 👉 Swipe to learn more 🔗 Full paper: https://bit.ly/4oeme0A

Last week, we got together to focus on a key part of TB research: advancing animal models. Six ERA4TB experts discussed how ethical animal models can drive better treatments for drug-resistant TB and speed up testing of new therapies. While the webinar was internal, the impact is global.

The honest reality check on AMR transmission models every researcher needs. Clarity on what works, what is missing and how to build trust. 👉 Swipe to learn the insights 👉 Read more: bit.ly/46UMqXO #AMR #TB #antimicrobialresistance #research

Juan Calvet (@uc3m.es) presented a poster on the integration of molecular biomarkers into time-kill assays for evaluating new anti-TB drug candidates. @amr-accelerator.bsky.social @ihieurope.bsky.social #Tuberculosis #TB #TranslationalResearch #Biomarkers #TimeKillAssays

I was taking 23 pills every day for 10 months.” A TB survivor shared this at ERA4TB’s MDR-TB dialogue. Behind every protocol is a person. That’s why we say “people affected by TB” or “TB survivors”. Language shifts power, from object to partner. Research must listen and build with communities.

We can’t fight 21st-century superbugs with 20th-century methods. Machine learning now predicts not just if a molecule is antimicrobial, but what class it targets. A COMBINE study shows how ML speeds smarter screening in early discovery. 👉 Swipe to learn more 👉 Read at: https://bit.ly/3GOfqFW

Immigration to Europe rose 33–50% in a decade. But, TB rates in migrants dropped by 28%. The concern of most of TB cases among immigrants is because native TB fell sharply and migrants often come from TB-endemic regions. Learn more from the discussion conducted by UNITE4TB: https://bit.ly/3UcaAFA

Great things happen in great partnerships, especially public–private ones. But not all are complete… yet! The AMR Accelerator asks: How can Europe bridge key gaps in antimicrobial resistance research? 👉 Read the new open access paper now: https://bit.ly/3TqqSdM

We are proud to be a part of a scientific data management platform called 𝗴𝗿𝗶𝘁, grit42’s open-source data platform. Via the COMBINE, GNA NOW & ERA4TB projects, we aim to make our scientific research more collaborative and impactful for all. 👉 For details: https://bit.ly/3TQOati

𝗦𝗮𝗺𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. How do we get TB dosing right for everyone? Our latest UNITE4TB study, led by Andrii Dudnyk, shows how drug monitoring & modelling support safer and smarter TB treatment. 🔗 bit.ly/4nv255T July 3, 2025 at 7:10 AM

Hear from Quentin Leclerc, as he shares how he’s using data, equations and tools to guide AMR interventions In this interview, he talks about: 🔬 Data-driven Modelling 🤝 Cross-disciplinary Collaboration 💡 Innovative Problem-Solving 🔗 Read full interview: https://bit.ly/3ZV5hxE

𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗱𝗮𝘁𝗮 𝗶𝘀 𝘁𝗼𝘂𝗴𝗵. 𝗥𝗲𝘂𝘀𝗶𝗻𝗴 𝗶𝘁? 𝗘𝘃𝗲𝗻 𝘁𝗼𝘂𝗴𝗵𝗲𝗿! Our new PrIMAVeRa study, explores how mAbs & vaccines impact antimicrobial resistance and tackles the real-world roadblocks to data sharing with practical fixes. 👉 What’s getting in the way? How do we solve it?

Hear from Carina Matias, as she shares her contribution is shaping reproducibility and clinical relevance in AMR research via COMBINE Project. In this interview, she provides insight into: 🧪 Drug Development 🤝 Global Collaboration 💻 AI Discovery 🔗 Read full interview: https://bit.ly/4lknOvI

𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝗧𝗕 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮 𝗺𝗼𝗿𝗲 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆? This work presents a protocol that combines two methods to better quantify MTB in time-kill assays. 🔍 More accurate data = better TB drugs. ⠀ 👉 𝗦𝘄𝗶𝗽𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗵𝗼𝘄 𝘄𝗲 𝗱𝗼 𝗶𝘁. @era4tb.bsky.social

Don't miss the chance to attend the UNITE4TB webinar! Join to learn on revolutionizing TB diagnosis: moving beyond sputum with innovative, noninvasive tools that improve detection, guide care and drive change.   🗓️ 26 June 2025 ⏰ 13:00-14:00 CEST   🔗 Register now: bit.ly/3FG8sm7

Same medicine, but different outcomes. Why does this happen and what can we do about it? In our recent work, we unpack interoccasion variability. A key factor in how we model drug behavior and build smarter clinical studies. 👉 Swipe to learn more.

Hear from Leonie von Berlin, as she shares how FAIR data practices power innovation across AMR Accelerator projects. In this interview, she talks about 🧬 Unified infrastructure 🤖 Enabling ML in antimicrobial R&D 🌍 Promoting open, global science 🔗 Read full interview: https://bit.ly/45zTOaD

Good luck to all the ERA4TB consortium members presenting at PAGE 2025 this week. www.page-meeting.org/default.asp?... #TBSky #TBResearch #Tuberculosis

How far can a petri dish take us in the fight against MRSA? 🧫 Using translational modelling, from in vitro to mouse models, we go further than you’d think ! Have a look at: 🔍 What we did 💡 Why it matters 🚀 Where it leads More about the paper on our site. amr-accelerator.eu/publications/